缓释性辅料市场规模、份额和成长分析（按类型、技术、给药途径和地区划分）－2026-2033年产业预测

预计到 2024 年，缓释辅料市场规模将达到 17.3 亿美元，到 2025 年将达到 18.7 亿美元，到 2033 年将达到 34.9 亿美元，预测期（2026-2033 年）的复合年增长率为 8.1%。

缓释性辅料市场是製药业的重要组成部分，专注于生产缓释性製剂所需的关键辅料。这些製剂能够促进药物的持续释放，进而减少给药频率，同时提高患者遵从性和治疗效果。在慢性病发病率上升、对创新给药系统的需求以及缓释性发展趋势的推动下，该市场持续扩张。辅料研发的进步，包括新型聚合物和包覆技术的出现，正在为生产商拓展製剂选择。主要企业正加大研发投入，以提高辅料的性能及其与各种活性药物成分的相容性。北美和欧洲市场占据主导地位，而亚太和拉丁美洲市场则因医疗保健服务的改善和製药技术的进步而呈现强劲增长。在精准医疗和个人化治疗的推动下，该市场的未来前景依然乐观。

缓释性辅料市场驱动因素

人口老化加剧对缓释辅料市场产生了显着影响，因为人口结构的变化正在推动对专为老年人设计的医疗保健产品和药物的需求。这些辅料透过实现药物的持续释放发挥关键作用，有助于提高患者的用药依从性，并有效管理慢性疾病。随着医疗保健机构应对人口老化带来的独特挑战，针对老年患者需求的药物需求日益增长。预计这种持续的人口结构变化将维持製药业对缓释性辅料的强劲需求。

缓释辅料市场的限制

由于药品核准和分销流程受到严格监管，缓释辅料市场面临许多障碍。这种复杂的法规环境给寻求将新产品推向市场的公司带来了巨大挑战。在确保符合现有法规的前提下获得必要的核准可能是一个漫长而昂贵的过程，而且充满挑战。此外，监管标准和指南的频繁变更可能会扰乱产品开发进度，阻碍市场准入，最终抑制市场成长。这些因素共同导致相关人员难以有效驾驭市场，并可能扼杀产业创新。

缓释性添加剂市场趋势

受个人化医疗日益增长的关注，缓释辅料市场正经历显着的发展趋势。随着製药业越来越重视开发针对个别患者需求的药物，缓释辅料的创新至关重要。这些辅料能够实现精准给药和最佳释放时间，从而提高疗效并减少副作用。这种以患者为中心的医疗保健模式不仅凸显了客製化给药系统的重要性，也促进了辅料製剂技术和製程的进步。因此，随着个人化治疗方案的不断发展，预计该市场将迎来强劲成长。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 案例研究

全球缓释性辅料市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 明胶
• 聚合物
• 矿物
• 糖
• 其他的

全球缓释性辅料市场规模（依技术及复合年增长率划分）（2026-2033 年）

• 精准投放
• 微胶囊化
• 伍斯特方法
• 其他的

全球缓释性辅料市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

• 口服
• 肌肉内注射
• 皮下注射
• 经皮
• 静脉注射
• 其他的

全球缓释性辅料市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• International Flavors & Fragrances Inc.（United States）
• Evonik Industries AG（Germany）
• BASF SE（Germany）
• Kerry Group Plc（Ireland）
• Roquette Freres（France）
• Merck KGaA（Germany）
• Associated British Foods Plc（United Kingdom）
• ADM（United States）
• Wacker Chemie AG（Germany）
• Croda International Plc（United Kingdom）
• Gattefosse（France）
• Colorcon Inc.（United States）
• AstraZeneca PLC（United Kingdom）
• GlaxoSmithKline PLC（United Kingdom）
• Mayne Pharma Group Limited（Australia）
• Sun Pharmaceutical Industries Ltd.（India）
• Pfizer Inc.（United States）
• Novartis AG（Switzerland）

结论与建议

Sustained Release Excipients Market size was valued at USD 1.73 Billion in 2024 and is poised to grow from USD 1.87 Billion in 2025 to USD 3.49 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).

The sustained release excipients market represents a critical segment of the pharmaceutical industry, emphasizing the production of excipients essential for sustained release formulations. These formulations facilitate gradual drug release, enhancing patient adherence and therapeutic efficacy while minimizing dosing frequency. The market is expanding, propelled by the rising incidence of chronic diseases, the demand for innovative drug delivery systems, and the trend towards controlled-release formulations. Technological advancements in excipient development, including new polymers and coatings, enhance formulation options for manufacturers. Major players invest in R&D to innovate excipient performance and compatibility with various active pharmaceutical ingredients. Geographically, North America and Europe lead the market, with strong growth emerging in Asia-Pacific and Latin America, fueled by improved healthcare access and pharmaceutical advancements. The future outlook remains bright, driven by a focus on precision medicine and personalized therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Sustained Release Excipients market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Sustained Release Excipients Market Segments Analysis

Global Sustained Release Excipients Market is segmented by Type, Technology, Route of Administration and region. Based on Type, the market is segmented into Gelatin, Polymers, Minerals, Sugars and Others. Based on Technology, the market is segmented into Targeted Delivery, Microencapsulation, Wurster Technique and Others. Based on Route of Administration, the market is segmented into Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Sustained Release Excipients Market

The growing elderly population is significantly influencing the sustained release excipients market, as demographic changes lead to an increased need for healthcare products and pharmaceuticals tailored to older individuals. These excipients play a crucial role by allowing extended drug release, which enhances patient compliance and effectively manages chronic health conditions. As healthcare providers respond to the unique challenges presented by an aging demographic, there is a rising demand for medications designed specifically to meet the needs of senior patients. This ongoing shift in demographics is expected to sustain a robust demand for sustained release excipients within the pharmaceutical industry.

Restraints in the Sustained Release Excipients Market

The sustained release excipients market faces significant obstacles due to stringent regulations that oversee drug approval and release processes. This complex regulatory environment presents a major hurdle for companies aiming to bring new products to market. The lengthy and costly process of securing necessary approvals while ensuring compliance with existing regulations can be challenging. Additionally, frequent changes in regulatory standards and guidelines can disrupt product development timelines and hinder market entry, ultimately impeding the growth of the market. This combination of factors makes it difficult for stakeholders to navigate the market effectively and can stifle innovation within the industry.

Market Trends of the Sustained Release Excipients Market

The sustained release excipients market is experiencing a notable trend driven by the increasing focus on personalized medicine. As the pharmaceutical industry places greater emphasis on tailoring medications to individual patient needs, innovations in sustained release excipients have become essential. These excipients allow for precise dosing and optimal release timing, enhancing therapeutic efficacy and reducing side effects. This shift towards patient-centric healthcare not only underscores the importance of customized drug delivery systems but also stimulates advancements in excipient formulations and technologies. As a result, the market is poised for robust growth, aligning with the evolving landscape of personalized therapeutic solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Sustained Release Excipients Market Size by Type & CAGR (2026-2033)

• Market Overview
• Gelatin
• Polymers
• Minerals
• Sugars
• Others

Global Sustained Release Excipients Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Targeted Delivery
• Microencapsulation
• Wurster Technique
• Others

Global Sustained Release Excipients Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intramuscular
• Subcutaneous
• Transdermal
• Intravenous
• Others

Global Sustained Release Excipients Market Size & CAGR (2026-2033)

• North America (Type, Technology, Route of Administration)
  • US
  • Canada
• Europe (Type, Technology, Route of Administration)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Technology, Route of Administration)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Technology, Route of Administration)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Technology, Route of Administration)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• International Flavors & Fragrances Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evonik Industries AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BASF SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kerry Group Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roquette Freres (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Associated British Foods Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADM (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wacker Chemie AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Croda International Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gattefosse (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Colorcon Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations